Combination of Suicide and Cytokine Gene Therapies as Surgery Adjuvant for Canine Mammary Carcinoma

Finocchiaro, Liliana M.E.; Spector, Agustina I M; Agnetti, Lucrecia; Arbe, María Florencia; Glikin, Gerardo C.

doi:10.3390/vetsci5030070

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another clinical trial with dogs presenting CMC utilized nanoparticles carrying DNA plasmids coding canine interferon-β and herpes simplex virus (HSV) thymidine kinase (a suicide gene), which were injected into the tumor bed during mastectomy; afterwards, subcutaneous injections of the nanoparticles associated with a human granulocyte–macrophage colony-stimulating factor and interleukin-2, mixed with allogeneic mammary carcinoma extracts, were periodically administered. The therapy was well-tolerated; only one out of 26 patients had recurrence and none displayed distant metastasis, and overall survival was also improved ( 334 ).…”

Section: Immunotherapy As a Progressing Targetmentioning

confidence: 99%

From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review

et al. 2021

View full text Add to dashboard Cite

Canine mammary tumors (CMTs) are the most common neoplasm in intact female dogs. Canine mammary cancer (CMC) represents 50% of CMTs, and besides surgery, which is the elective treatment, additional targeted and non-targeted therapies could offer benefits in terms of survival to these patients. Also, CMC is considered a good spontaneous intermediate animal model for the research of human breast cancer (HBC), and therefore, the study of new treatments for CMC is a promising field in comparative oncology. Dogs with CMC have a comparable disease, an intact immune system, and a much shorter life span, which allows the achievement of results in a relatively short time. Besides conventional chemotherapy, innovative therapies have a large niche of opportunities. In this article, a comprehensive review of the current research in adjuvant therapies for CMC is conducted to gather available information and evaluate the perspectives. Firstly, updates are provided on the clinical–pathological approach and the use of conventional therapies, to delve later into precision therapies against therapeutic targets such as hormone receptors, tyrosine kinase receptors, p53 tumor suppressor gene, cyclooxygenases, the signaling pathways involved in epithelial–mesenchymal transition, and immunotherapy in different approaches. A comparison of the different investigations on targeted therapies in HBC is also carried out. In the last years, the increasing number of basic research studies of new promising therapeutic agents on CMC cell lines and CMC mouse xenografts is outstanding. As the main conclusion of this review, the lack of effort to bring the in vitro studies into the field of applied clinical research emerges. There is a great need for well-planned large prospective randomized clinical trials in dogs with CMC to obtain valid results for both species, humans and dogs, on the use of new therapies. Following the One Health concept, human and veterinary oncology will have to join forces to take advantage of both the economic and technological resources that are invested in HBC research, together with the innumerable advantages of dogs with CMC as a spontaneous animal model.

show abstract

Section: Immunotherapy As a Progressing Targetmentioning

confidence: 99%

From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For veterinary use, another important breakthrough is the treatment of canine melanoma with a combination of chemo-gene therapy and cytokine-enhanced vaccine in a new surgery adjuvant combined gene therapy (Finocchiaro et al 2019). Furthermore, suicide and cytokine gene therapies were another combination for adjuvant gene therapy for canine mammary carcinoma (Finocchiaro et al 2018).…”

Section: Vaccines and Gene Therapymentioning

confidence: 99%

Responsible Innovation in Industry: The Role of Firm’s Multi-Stakeholder Network

et al. 2021

View full text Add to dashboard Cite

the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

Genomic Vaccines for Pandemic Diseases in Times of COVID-19: Global Trends and Patent Landscape

et al. 2021

View full text Add to dashboard Cite

Combination of Suicide and Cytokine Gene Therapies as Surgery Adjuvant for Canine Mammary Carcinoma

Cited by 5 publications

References 21 publications

From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review

From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review

Responsible Innovation in Industry: The Role of Firm’s Multi-Stakeholder Network

Genomic Vaccines for Pandemic Diseases in Times of COVID-19: Global Trends and Patent Landscape

Contact Info

Product

Resources

About